Edoxabn is a reversible factor Xa inhibitor with high selectivity. During coagulation, factor Xa forms a prothrombinase complex with factor Va on the surface of platelets . Prothrombinase converts prothrombin to thrombin, which in turn converts soluble fibrinogen to insoluble fibrin, the main component of blood clots. Thus, FXa has become a major target for the development of a new generation of anticoagulants.